Farmacoeconomia ed etica: cure sostenibili e rispetto della persona

The scarcity of economic resources today is a fundamental problem in public healthcare. The importance of making well-founded choices for optimal resources allocation concerns also pharmacological treatments and is justified also on ethical grounds, besides the economic, political and/or medical considerations. In fact, a better management, also in economic sense, of the patient and sickness involves the possibility of offering an efficient treatment to all the sick, or at least to as many of them as possible. However, these considerations should always be subordinated to the ethical centrality of the patient, to the protection of his life, his health and his personal dignity, to the extent that life and health are priceless. The goal of ethics in pharmacoeconomics can be summarised in respect for the person, which must remain the end and reference of every therapeutic choice as well as every healthcare policy. The indispensable instruments for the realisation of the above objectives are, amongst others, those already highlighted but which demand further explanation: a) a suitable standard background/training and a multidisciplinary approach for optimising the evaluation procedures and increasing accuracy and verifiableness of the data; b) measures to contrast and disclose the conflict of interest for more transparency and credibility; c) a coherent evaluation of the ethical quality and humanness of the pharmacoeconomic analysis which requires a correct consideration of quality of life and a real respect for persons

Ethical considerations regarding head transplantation

N/

Ethical considerations regarding head transplantation

N/

Allogeneic versus Autologous: ethical issues in umbilical cord blood use

OBJECTIVE. To analyse some ethical issues involved in umbilical cord blood (UCB) collection, storage and use. MATERIALS AND METHODS. Ethical issues were addressed in the light of the wellknown fundamental ethical principles for biomedicine: beneficence/non maleficence, respect for autonomy and justice. Specific issues that have been debated concerning the clinical utility of autologous use compared with allogeneic use for transplantation, the validity of informed consent, especially in private UCB banking, and finally the controversial question of private UCB banking for-profit compared to public UCB banking non-profit. RESULTS. Our ethical analysis has highlighted that the allogeneic UCB use for transplantation, compared to autologous UCB use, seems to fulfil the principle of beneficence/non maleficence as it provides “logistic” and clinical benefits and it decreases risks; the acquisition of informed consent requires some counselling, particularly for autologous collection; finally, public UCB banking seems to fulfil the criteria for justice more than private ones. CONCLUSION. Present and future therapeutic UCB possibilities for treating a wide variety of diseases need to increase the number of UCB units available. For this purpose, a “gift” culture and a “solidarity chain” between donors and recipients are requested. Moreover, in recent years, a further and emerging model of bank seems usable, i.e. “hybrid” banking

Nunziata Comoretto, Antonio G.Spagnolo, “Il nuovo Codice deontologico dell\u27infermiere : una lettura etico-deontologica”(traduzione)

医師の専門職的・道徳的義務の上に強い圧力を働かせる現代医学の増大する科学技術力と，過去数十年間にわたって全西洋諸国を特徴づけてきた深い社会的・文化的変化の双方は，恒常的，持続的にアップデートされた看護についての倫理的考察を要求する。看護師の新職業倫理規程の最近の公布は，看護の倫理的・職業倫理的側面についての注意深い考察へと駆り立てる。過去数十年間，そのような側面は，専門職の目的やそれに関連する価値よりも生産市場の視点に従って，官僚主義的および経済的側面にのみ集中する危険にさらすような，技術的性能や生産性への注目の優越によって，強く脅かされる結果を生じた。それゆえ，自らの目的と価値を考察する専門職の表現である職業倫理規程は，看護職を社会全体のための専門職として引き受ける責務（commitment）についての考察へと導く最も適切な道具になる。新職業倫理規程は，看護師の倫理的実践にとって重要な多くの手がかりを導入している。本稿は，人間的な患者のケアについての倫理的考察の重要性を深く学びつつ，新職業倫理規程の倫理的・職業倫理的解釈を提示しようとするものである

health technology assessment processes for nanotechnologies the ethical domain

The ethical assessment of the use of technologies is generally considered a component of the health technology assessment (HTA) processes. HTA is a multidisciplinary process that summarizes information about medical, economic, organizational, ethical, psychological, social and legal issues related to the implementation of a certain health technology in health care system and its main purpose is to inform policymaking. Unlike the other technologies nanotechnologies pose different risks and, therefore, new bioethical implications should be assessed. So, the ethical assessment of nanotechnologies within the HTA processes could be more problematic. The article intends to debate this complexity

Health technology assessment of pathogen reduction technologies applied to plasma for clinical use

Although existing clinical evidence shows that the transfusion of blood components is becoming increasingly safe, the risk of transmission of known and unknown pathogens, new pathogens or re-emerging pathogens still persists. Pathogen reduction technologies may offer a new approach to increase blood safety. The study is the output of collaboration between the Italian National Blood Centre and the Post-Graduate School of Health Economics and Management, Catholic University of the Sacred Heart, Rome, Italy. A large, multidisciplinary team was created and divided into six groups, each of which addressed one or more HTA domains.Plasma treated with amotosalen + UV light, riboflavin + UV light, methylene blue or a solvent/detergent process was compared to fresh-frozen plasma with regards to current use, technical features, effectiveness, safety, economic and organisational impact, and ethical, social and legal implications. The available evidence is not sufficient to state which of the techniques compared is superior in terms of efficacy, safety and cost-effectiveness. Evidence on efficacy is only available for the solvent/detergent method, which proved to be non-inferior to untreated fresh-frozen plasma in the treatment of a wide range of congenital and acquired bleeding disorders. With regards to safety, the solvent/detergent technique apparently has the most favourable risk-benefit profile. Further research is needed to provide a comprehensive overview of the cost-effectiveness profile of the different pathogen-reduction techniques. The wide heterogeneity of results and the lack of comparative evidence are reasons why more comparative studies need to be performed

Experimental Quantum Hamiltonian Learning

Efficiently characterising quantum systems, verifying operations of quantum devices and validating underpinning physical models, are central challenges for the development of quantum technologies and for our continued understanding of foundational physics. Machine-learning enhanced by quantum simulators has been proposed as a route to improve the computational cost of performing these studies. Here we interface two different quantum systems through a classical channel - a silicon-photonics quantum simulator and an electron spin in a diamond nitrogen-vacancy centre - and use the former to learn the latter's Hamiltonian via Bayesian inference. We learn the salient Hamiltonian parameter with an uncertainty of approximately $10^{-5}$. Furthermore, an observed saturation in the learning algorithm suggests deficiencies in the underlying Hamiltonian model, which we exploit to further improve the model itself. We go on to implement an interactive version of the protocol and experimentally show its ability to characterise the operation of the quantum photonic device. This work demonstrates powerful new quantum-enhanced techniques for investigating foundational physical models and characterising quantum technologies

Measurements of Higgs boson production and couplings in diboson final states with the ATLAS detector at the LHC

Measurements are presented of production properties and couplings of the recently discovered Higgs boson using the decays into boson pairs, H →γ γ, H → Z Z∗ →4l and H →W W∗ →lνlν. The results are based on the complete pp collision data sample recorded by the ATLAS experiment at the CERN Large Hadron Collider at centre-of-mass energies of √s = 7 TeV and √s = 8 TeV, corresponding to an integrated luminosity of about 25 fb−1. Evidence for Higgs boson production through vector-boson fusion is reported. Results of combined fits probing Higgs boson couplings to fermions and bosons, as well as anomalous contributions to loop-induced production and decay modes, are presented. All measurements are consistent with expectations for the Standard Model Higgs boson